News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kucera Pharmaceutical Is Issued U.S. Patent


10/19/2005 5:09:40 PM

WINSTON-SALEM, N.C., Jan. 14 /PRNewswire/ -- The Kucera Pharmaceutical Company announced today the issuance of a patent by the U.S. Patent and Trademark Office entitled "Compositions and Methods for Double-targeting Virus Infections and Targeting Cancer Cells" (6,670,341). "The technology within this patent can improve the efficacy and safety of a number of antiviral, anticancer, and other therapeutic compounds," said Dr. Ronald Fleming, Chief Scientific Officer.

"This is the 6th U.S. patent issued for the company," said Russ H. Read, Kucera CEO. "Our intellectual property base continues to grow. Our team is highly focused on building value through Kucera chemistry and its initial applications in virology and cancer."

Kucera Pharmaceutical Co. (http://www.kucerapharma.com/), a 2001 spin-off of Wake Forest University Health Sciences and the University of North Carolina at Chapel Hill, has in development patented antiviral small molecules. It also has anticancer agents in development.

Kucera is headquartered at the Piedmont Triad Research Park (http://www.ptrp.org/) in downtown Winston-Salem and has laboratories at Phase 3 Properties, Inc. in Durham, N.C.

CONTACT: Russ H. Read, CEO Kucera Pharmaceutical Co. (336) 723-7133 Dr. Ronald A. Fleming Chief Scientific Officer Kucera Pharmaceutical Co. (336) 403-6819

Kucera Pharmaceutical Company

CONTACT: Russ H. Read, CEO, +1-336-723-7133; or Dr. Ronald A. FlemingChief Scientific Officer, +1-336-403-6819, both of Kucera Pharmaceutical Co.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES